Lemborexant Market
The market for Lemborexant was estimated at $332 million in 2024; it is anticipated to increase to $496 million by 2030, with projections indicating growth to around $692 million by 2035.
Global Lemborexant Market Outlook
Revenue, 2024
Forecast, 2034
CAGR, 2025 - 2034
The Lemborexant industry revenue is expected to be around $355.0 million in 2025 and expected to showcase growth with 6.9% CAGR between 2025 and 2034. The rising need for Lemborextant highlights its role in the healthcare industry. Its market growth is driven by its effectiveness in addressing sleep disorders like insomnia. The increasing prevalence of sleep related issues worldwide coupled with awareness and availability of effective treatment choices have strengthened its continued importance. Given that sleep problems are now acknowledged as a global health concern there is no indication that Lemborextants position, as a therapeutic remedy will diminish, ensuring its enduring market relevance regardless of economic fluctuations. The emphasis on health and wellness has increased the value of delivering treatments like Lemborextant to meet a crucial demand, in modern society.
The dual orexin receptor antagonist known as Lemborext offers a range of features that highlight its popularity among users and healthcare providers alike. The primary use of this medication in treating insomnia underscores its effectiveness, in enhancing the quality of sleep.
Market Key Insights
- The Lemborexant market is projected to grow from $332.1 million in 2024 to $647 million in 2034. This represents a CAGR of 6.9%, reflecting rising demand across Insomnia Treatment, Narcolepsy Management and Circadian Rhythm Sleep Disorder Management.
- Eisai Co. Ltd, Pfizer Inc, Takeda Pharmaceutical Company Limited are among the leading players in this market, shaping its competitive landscape.
- U.S. and Japan are the top markets within the Lemborexant market and are expected to observe the growth CAGR of 4.5% to 6.6% between 2024 and 2030.
- Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 7.9% to 9.5%.
- Transition like Evolution towards Personalized Medicine has greater influence in U.S. and Japan market's value chain; and is expected to add $17 million of additional value to Lemborexant industry revenue by 2030.
- The Lemborexant market is set to add $315 million between 2024 and 2034, with manufacturer targeting Narcolepsy & Circadian rhythm disorders Treatment Areas projected to gain a larger market share.
- With Rising prevalence of insomnia and sleep-related disorders, and Advancements in medical research and drug formulation, Lemborexant market to expand 95% between 2024 and 2034.
